Efficacy of Amoxicillin/Clavulanate Potassium in Treating Lower Respiratory Tract Infection (70 Cases)

Objective:To study the therapeutical efficacy of amoxicillin/clavulanate potassium chewable tablets (CPA) in treating lower respiratory tract infection by comparing with the efficacy of cefaclor. Methods:A total of 130 patients were randomly divided into two groups: 70 patients in the treatment group received CPA 0.5 g tid; 60 patients as the control group received cefaclor 0.25 g tid, both for 7～14 days. The efficacy and safety of the two groups were evaluated. Results:Therapeutic courses of the treatment group and the control groups lasted (9.5±3.3) days and (9.1±3.3) days respectively. There was no statistically significant difference ( P 0.05). Effective rate of the treatment group was 92.8%, and that of the control group was 80.0%. Bacterial clearance rates of the two groups were 91.4% and 71.6% respectively. No obvious adverse reaction was found during the therapeutical period. Conclusion:Amoxicillin/clavulanate potassium has a good therapeutical effect in treating lower respiratory tract infection with safety. It is worthy of spreading.